[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100373296":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":42,"responsibleParty":56,"collaborators":18,"id":58,"slug":18,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":18,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":80,"overallStatus":45,"whyStopped":18,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Antibiotic","EXPERIMENTAL","Participate will be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration",[13],"Drug: Ertapenem",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","Participate will not be acepted ertapenem(1g) iv before endoscopic cyanoacrylate injection obliteration",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Ertapenem","inject from iv drip before endoscopic cyanoacrylateinjection obliteration",[9],[26],"Invanz",[28],{"name":29,"affiliation":5,"role":30},"Ming-Chih Hou","PRINCIPAL_INVESTIGATOR",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Ming-Chih Hou, MD","CONTACT","886-2-28712111","7877","mchou@vghtpe.gov.tw",{"name":39,"role":34,"phone":35,"phoneExt":40,"email":41},"Pei-Chang Lee, MD","3972","pclee7@vghtpe.gov.tw",[43],{"facility":44,"status":45,"city":46,"state":18,"zip":18,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Veteran General Hospital-Taipei","RECRUITING","Taipei","Taiwan",{"type":49,"coordinates":50},"Point",[51,52],121.52639,25.05306,{"lat":52,"lon":51},[55],{"name":29,"role":34,"phone":18,"phoneExt":18,"email":18},{"type":57,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100373296",false,"NCT04140578","Antibiotic Prophylaxis in Patients Undergoing GVO","Antibiotic Prophylaxis in Patients Undergoing Endoscopic Injection of Cyanoacrylate for Primary and Secondary Prevention of Gastric Variceal Bleeding","ABX-GV","Inclusion Criteria:\n\n1. Patients with live cirrhosis and\u002For hepatoma\n2. Aged 20 to 85, who had endoscopy-treatment EV(-)GV(+)or EV\\\u003CGV\n\nExclusion Criteria:\n\n1. Had a terminal illness of any major organ system,such as heart failure, kindey failure,COPD\n2. Patients recieve antibiotics recently.\n3. Patients suspected infection.","ALL","20 Years","85 Years",{"count":69,"type":70},150,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","We design a randomized trial to clarify the necessity of antibiotic prophylaxis for the patients chronic liver disease with gastric varices treated by elective GVO.",[76,77,78,79],"Gastric Varix","Sepsis","Liver Cirrhoses","Fever",[81,77,82],"Gastric variceal rebleeding","cyanoacrylate injection","2019-10-24",{"date":85,"type":86},"2019-10-28","ACTUAL",{"date":88,"type":86},"2017-01-28",{"date":90,"type":70},"2030-12-31",{"name":5,"class":6},1]